| Name | Shield Therapeutics |
|---|---|
| Epic | STX |
| Isin | GB00BYV81293 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 2.75p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £21.51 | Debt ratio | n/a |
| Shares in issue | 782.06 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | 5574.34 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -17 | 52-week high / low | 1.23p / 7.65p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Shield Therapeutics |
|---|---|
| Address | Northern Design Centre, Baltic Business Quarter, Gateshead Quays, United Kingdom, NE8 3DF |
| Telephone | +44 (0) 191 511 8500 |
| Website | http://www.shieldtherapeutics.com/ |
| Director | Position |
|---|---|
| Dr Christian Schweiger | Non-Executive Director |
| Mr Hans-Peter Hasler | Non-Executive Chairman |
| Mr Greg Madison | Group Chief Executive |
| Mr Peter Llewellyn-Davies | Independent Non-Executive Director |
| Mr Anders Lundstrom | Independent Non-Executive Director |
| Mrs Fabiana Lacerca Allen | Independent Non-Executive Director |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 11.78 | 26.85 | 27.27 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 11.98 | 27.16 | 27.3 |
| Inventory / work in progress | 1.46 | 1.64 | 1.38 |
| Trade and other receivables | 5.38 | 2.93 | 0.62 |
| Cash and equivalents | 2.82 | 12.12 | 2.94 |
| Other current assets and asset held for resale | 0.44 | 0.58 | 0.29 |
| Total of all assets | 22.07 | 44.41 | 32.53 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 10.64 | 3.72 | 2.25 |
| Long term liabilities | 6.01 | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 16.65 | 3.72 | 2.25 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 5.43 | 40.69 | 30.28 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 3.89 | 3.24 | 1.76 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -146.64 | -106.94 | -88.25 |
| Share premium account | 116.26 | 114.58 | 88.35 |
| Total equity | 5.43 | 40.69 | 30.28 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -40.41 | -20.29 | -2.15 |
| Pre-tax profit | -40.08 | -19.91 | -1.89 |